Evidence map›Paper›PMID 38807770›Full record

ArticleFrontiers in oncology2024

Immunohistochemistry analysis of PSMA expression at prostatic biopsy in high-risk prostate cancer: potential implications for PSMA-PET patient selection.

Matteo Droghetti, Lorenzo Bianchi, Massimiliano Presutti, Luigia Vetrone, Andrea Farolfi, Riccardo Mei, Francesca Giunchi, Alessio Degiovanni, Angelo Mottaran, Pietro Piazza and 6 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Matteo Droghetti *Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Lorenzo Bianchi *Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Massimiliano PresuttiDivision of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Luigia VetroneNuclear Medicine, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
Andrea FarolfiNuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Riccardo MeiNuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Francesca GiunchiPathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Alessio DegiovanniPathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Angelo MottaranDivision of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Pietro PiazzaDivision of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Danilo CangemiDivision of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Paolo CastellucciNuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Antonietta D'ErricoPathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Riccardo SchiavinaDivision of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Eugenio BrunocillaDivision of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Stefano FantiUniversità degli Studi di Bologna, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Prostate-specific membrane antigen (PSMA) is a transmembrane protein expressed by normal prostatic tissue. Therefore, molecular imaging targeting PSMA (PSMA-PET) has gained particular interest and diffusion for PCa staging and restaging. Several factors may affect PSMA-PET results, and many tools have been proposed to improve patient selection. Furthermore, PSMA expression is not homogeneous among different tissues and within the prostate itself. The aims of this study were to evaluate immunohistochemistry (IHC) features of prostate biopsy samples and to assess their correlation with whole-mount specimens and PSMA-PET parameters. Methods: We included consecutive high-risk PCa patients who underwent PSMA-PET for staging proposal at our institution from January 2022 to December 2022. The PET parameters selected were SUVmax, total volume (TV), and total lesion activity (TL). Each patient underwent multiparametric MRI (mpMRI) and fusion-targeted prostate biopsy prior to surgery. IHC analyses were performed on the index lesion cores. IHC visual score (VS) (1, 2, 3) and visual pattern (VP) (membranous, cytoplasmic, and combined) and the percentage of PSMA-negative tumor areas (PSMA%neg) within biopsy cores were evaluated. Results: Forty-three patients who underwent robotic radical prostatectomy after PSMA-PET were available for analyses. Concordance between VS and VP at biopsy and final pathology showed a Cohen's kappa coefficient of 0.39 and 0.38, respectively. Patients with PSMA%neg <20% had a higher concordance in VS and VP (Cohen's kappa 0.49 and 0.4, respectively). No difference emerged in terms of median PSMA-TV ( Conclusions: We found a correlation between IHC VS and VP on targeted biopsy cores and SUVmax at PSMA-PET. However, the correlation between the IHC parameters of biopsy cores and final pathology was not as high as expected. Nevertheless, the presence of PSMA%neg <20% seems to have a better concordance in terms of visual score.

Indexed as

biopsyimmunohistochemistryprostate cancerPSMA PETradical prostatectomy

Identifiers

PMID38807770
PMCPMC11130476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.